Sofinnova Venture Partners X L.P. 13D and 13G filings for Inozyme Pharma, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-20 7:11 pm Purchase | 2023-07-28 | 13D | Inozyme Pharma, Inc. INZY | Sofinnova Venture Partners X L.P. | 4,280,308 6.900% | 2,252,000 (+111.03%) | Filing |
| 2021-03-04 06:20 am Purchase | 2020-07-28 | 13D | Inozyme Pharma, Inc. INZY | Sofinnova Venture Partners X L.P. | 2,028,308 8.700% | 2,028,308 (New Position) | Filing |